2022-RA-1352-ESGO Dose received by axillary lymph nodes in breast cancer adjuvant radiotherapy

Introduction/Background The axillary region is considered problematic; a risked organ (OAR), predictive dosimetric parameter of long-term lymphedema, and residual-disease site in case breast-cancer radiotherapy.Our study endeavors to determine the dose received by area adjuvant radiotherapy for assess its clinical impact on lymphedema. Methodology A retrospective study, executed department Farhat Hached Hospital, Sousse, included 50 female patients treated with three-dimensional breast-cancer, between 2018 2019. axillary-area was delineated according European-Organization Research Treatment Cancer(EORTC) guidelines. Results average age 52[30–80]. 64% our had mastectomy ipsilateral lymph-node dissection(IALND), while 36% lumpectomy IALND. 35 patients(70%) regional 15 patients(30%) only local 2 tangential fields. All were normofractionated 50Gy. Patients conservative surgical treatment or T4 classified tumors an additional boost; 66Gy (21patients) 70Gy tumoral-surgical limits (1patient). mean volume 77.9 cm3[9.4–181]. mean-dose, maximal-dose minimal-dose respectively 28.49Gy[3.19–53.7Gy], 54.18Gy[33.96–72.63Gy] 9.4Gy[0.32–10.74Gy].Late complications lymphedema radio induced dermatitis (GI II CTCAEV5.0scale) observed 6(12%) 17(34%) patients. Conclusion To conclude, unintentional significant doses during breast-irradiation; fields supraclavicular field. Some authors consider that axillary-lateral thoracic vessel junction (ALTJ); that’s above level I Berg, as OAR can be minimized especially clinically node-negative Further validation parameters prospective studies justified.